{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:44:23Z","timestamp":1792547063812,"version":"4.5.0"},"reference-count":169,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104779","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:17:55Z","timestamp":1764263875000},"page":"104779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiotherapy for primary lung cancer: 2025 update"],"prefix":"10.1016","volume":"29","author":[{"given":"Jonathan","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"El Houat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Thureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Darr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Le P\u00e9choux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lerouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Marguerit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pourel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Georges","family":"Riet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104779_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtho.2020.09.012","article-title":"Lung cancer in France","volume":"16","author":"Pujol","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2025.104779_bib0015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-021-08261-1","article-title":"Cancer incidence and mortality trends in France over 1990\u20132018 for solid tumors: the sex gap is narrowing","volume":"21","author":"Defossez","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0025","series-title":"Cancer bronchique non \u00e0 petites cellules","year":"2025"},{"key":"10.1016\/j.canrad.2025.104779_bib0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.chest.2024.05.026","article-title":"The proposed ninth edition TNM classification of lung cancer","volume":"166","author":"Detterbeck","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.canrad.2025.104779_bib0035","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaoncol.2023.7269","article-title":"Stereotactic radiation therapy in early non-small cell lung cancer and interstitial lung disease: a nonrandomized clinical trial","volume":"10","author":"Palma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0060","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1378\/chest.128.4.2490","article-title":"Clinical prediction model to characterize pulmonary nodules: validation and added value of (18F)-fluorodeoxyglucose positron emission tomography","volume":"128","author":"Herder","year":"2005","journal-title":"Chest"},{"issue":"10405","key":"10.1016\/j.canrad.2025.104779_bib0065","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0070","first-page":"1","article-title":"Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I\/II non-small-cell lung cancer (NSCLC): the randomized, double-blind, phase 3 KEYNOTE-867 study","volume":"24","author":"Pircher","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0075","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.canrad.2023.07.012","article-title":"[Stereotactic radiotherapy for operable stage I non-small cell lung cancer]","volume":"27","author":"Martin","year":"2023","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0080","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0085","doi-asserted-by":"crossref","first-page":"108061","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2025.104779_bib0095","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0110","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le P\u00e9choux","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0125","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.21.01774","article-title":"Indications and parameters around postoperative radiation therapy for lung cancer","volume":"40","author":"Levy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.canrad.2025.104779_bib0135","doi-asserted-by":"crossref","first-page":"S939","DOI":"10.1016\/j.annonc.2021.08.1774","volume":"32","author":"Le P\u00e9choux","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0140","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2015.61.1517","article-title":"Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer","volume":"33","author":"Wang","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0150","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0155","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0160","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0165","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0170","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.canrad.2025.104779_bib0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canrad.2023.03.002","article-title":"Radiotherapy in the management of synchronous metastatic lung cancer","volume":"28","author":"Khalifa","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0180","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.canrad.2025.104779_bib0185","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer\u00a0\u2013\u00a0a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.canrad.2025.104779_bib0190","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0195","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0200","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104779_bib0205","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2025.104779_bib0210","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.prro.2018.02.009","article-title":"Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline","volume":"8","author":"Moeller","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0230","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7\u20138","key":"10.1016\/j.canrad.2025.104779_bib0235","doi-asserted-by":"crossref","first-page":"104757","DOI":"10.1016\/j.canrad.2025.104757","article-title":"Guidelines about radiation therapy and systemic treatments: stop or continue?","volume":"29","author":"Buchalet","year":"2025","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0245","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/cncr.20539","article-title":"Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study","volume":"101","author":"Onishi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0250","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0255","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0260","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0265","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2024.05.366","article-title":"Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results","volume":"19","author":"Levy","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0270","doi-asserted-by":"crossref","first-page":"109848","DOI":"10.1016\/j.radonc.2023.109848","article-title":"Ten years outcomes after SABR in central and ultracentral primary lung tumors","volume":"188","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0275","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.canrad.2023.06.021","article-title":"Stereotactic radiotherapy for ultracentral lung tumours","volume":"27","author":"Bourbonne","year":"2023","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0280","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0285","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0290","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs. hypofractionated radiotherapy for inoperable stage I non-small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0295","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0300","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104779_bib0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0310","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jnci\/87.3.198","article-title":"Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer","volume":"87","author":"Sause","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2025.104779_bib0315","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2025.104779_bib0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2024.09.1437","article-title":"Accelerated hypofractionated radiotherapy for locally advanced NSCLC: a systematic review from the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","volume":"20","author":"Said","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0325","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1200\/JCO.2012.41.6677","article-title":"Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis","volume":"30","author":"Mauguen","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0330","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs. conventional radiotherapy for patients with stage II\/III non-small cell lung cancer and poor performance status: a randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0335","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","article-title":"SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status","volume":"50","author":"Maguire","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0340","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2024.03.030","volume":"120","author":"Zhang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0345","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.radonc.2020.04.033","article-title":"Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I\/II study","volume":"148","author":"Glinski","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0350","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","article-title":"Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: CALGB 31102 (Alliance)","volume":"101","author":"Urbanic","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0355","doi-asserted-by":"crossref","first-page":"109492","DOI":"10.1016\/j.radonc.2023.109492","article-title":"(18F)-FDG-PET guided vs. whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-boost): results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0360","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo)radiotherapy using midtreatment (18F)-fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0365","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74\u00a0Gy) or standard radiotherapy (66\u00a0Gy) for patients with stage III non-small-cell lung cancer, according to (18F)-FDG-PET tumour residual uptake at 42\u00a0Gy (RTEP7\u2013IFCT-1402): a multicentre, randomised, controlled phase 2 trial","volume":"25","author":"Vera","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0370","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1067\/mtc.2001.112465","article-title":"Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"121","author":"Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.canrad.2025.104779_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.06.003","article-title":"European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.radonc.2015.03.014","article-title":"PET\/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014","volume":"116","author":"Konert","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0385","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0167-8140(00)00138-9","article-title":"The impact of (18F)-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer","volume":"55","author":"Vanuytsel","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0390","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0360-3016(01)01824-7","article-title":"The impact of (18F)-FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study","volume":"52","author":"Mah","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0395","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ijrobp.2004.12.019","article-title":"Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study","volume":"62","author":"De Ruysscher","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0400","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(24)00010-9","article-title":"Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial","volume":"12","author":"Steinfort","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemoradiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.canrad.2025.104779_bib0410","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.canrad.2006.05.009","article-title":"Reduction of organ motion effects in IMRT and conformal 3D radiation delivery by using gating and tracking techniques","volume":"10","author":"Giraud","year":"2006","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0415","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0167-8140(93)90235-Z","article-title":"A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data","volume":"29","author":"Boersma","year":"1993","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13014-016-0698-3","article-title":"Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)","volume":"11","author":"Li","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0425","first-page":"371819","article-title":"Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study","volume":"2013","author":"Chen","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.canrad.2025.104779_bib0430","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11684-007-0074-7","article-title":"Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT","volume":"1","author":"Yang","year":"2007","journal-title":"Front Med China"},{"key":"10.1016\/j.canrad.2025.104779_bib0435","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.coc.0000256691.27796.24","article-title":"A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non-small cell lung cancer","volume":"30","author":"Yuan","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0440","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104779_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0450","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0360-3016(00)00750-1","article-title":"Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning","volume":"48","author":"Giraud","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0455","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2006.08.057","article-title":"Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer","volume":"67","author":"Yuan","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0460","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1378\/chest.111.6.1718","article-title":"Regional lymph node classification for lung cancer staging","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.canrad.2025.104779_bib0465","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2004.12.060","article-title":"CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan","volume":"63","author":"Chapet","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jrr\/rrw076","article-title":"The Japan Lung Cancer Society-Japanese Society for Radiation Oncology consensus-based computed tomographic atlas for defining regional lymph node stations in radiotherapy for lung cancer","volume":"58","author":"Itazawa","year":"2017","journal-title":"J Radiat Res"},{"key":"10.1016\/j.canrad.2025.104779_bib0475","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0360-3016(00)00518-6","article-title":"The probability of correct target dosage: dose\u2013population histograms for deriving treatment margins in radiotherapy","volume":"47","author":"van Herk","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0480","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.clon.2012.05.007","article-title":"Intensity-modulated radiotherapy in the treatment of lung cancer","volume":"24","author":"Bezjak","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2025.104779_bib0485","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0490","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2019.11.001","article-title":"Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91","volume":"142","author":"de Jong","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0495","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13014-014-0223-5","article-title":"GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms","volume":"9","author":"Lacornerie","year":"2014","journal-title":"Radiat Oncol"},{"issue":"7\u20138","key":"10.1016\/j.canrad.2025.104779_bib0500","doi-asserted-by":"crossref","first-page":"104758","DOI":"10.1016\/j.canrad.2025.104758","article-title":"Delineation of organs at risk in radiotherapy and perspectives","volume":"29","author":"Eber","year":"2025","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0505","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0510","doi-asserted-by":"crossref","first-page":"20150100","DOI":"10.1259\/bjr.20150100","article-title":"Image-guided radiotherapy and motion management in lung cancer","volume":"88","author":"Korreman","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2025.104779_bib0515","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.canrad.2018.06.009","article-title":"[Image-guided radiotherapy in lung cancer]","volume":"22","author":"Aboudaram","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0520","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijrobp.2007.01.014","article-title":"Kilo-voltage cone-beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device","volume":"68","author":"Borst","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0525","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1118\/1.3598434","article-title":"Management of the baseline shift using a new and simple method for respiratory-gated radiation therapy: detectability and effectiveness of a flexible monitoring system","volume":"38","author":"Tachibana","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru\/os32.1.1","article-title":"ICRU Report 62: prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50)","volume":"os-32","author":"Landberg","year":"1999","journal-title":"J ICRU"},{"key":"10.1016\/j.canrad.2025.104779_bib0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru\/os26.1.1","article-title":"ICRU Report 50: prescribing, recording and reporting photon beam therapy","volume":"os-26","author":"Landberg","year":"1993","journal-title":"J ICRU"},{"key":"10.1016\/j.canrad.2025.104779_bib0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru_ndq002","article-title":"Report 83: prescribing, recording, and reporting intensity-modulated photon-beam therapy (IMRT)","volume":"10","year":"2010","journal-title":"J ICRU"},{"issue":"2","key":"10.1016\/j.canrad.2025.104779_bib0545","first-page":"1","article-title":"ICRU Report 91: prescribing, recording, and reporting of stereotactic treatments with small photon beams","volume":"14","year":"2014","journal-title":"J ICRU"},{"issue":"1\u20132","key":"10.1016\/j.canrad.2025.104779_bib0550","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104779_bib0555","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","article-title":"Clinical dose\u2013volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)","volume":"45","author":"Graham","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0560","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0565","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2001.19.19.3912","article-title":"Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma","volume":"19","author":"Machtay","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0570","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0360-3016(02)03986-X","article-title":"Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability","volume":"55","author":"Seppenwoolde","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0575","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-8140(03)00119-1","article-title":"Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study","volume":"67","author":"Rancati","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0580","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0585","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90\u00a0Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0590","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0595","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ijrobp.2022.11.033","article-title":"Left anterior descending coronary artery radiation dose association with all-cause mortality in NRG oncology trial RTOG 0617","volume":"115","author":"McKenzie","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0600","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104779_bib0605","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2020.06.031","article-title":"Novel methodology to investigate the effect of radiation dose to heart substructures on overall survival","volume":"108","author":"McWilliam","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0610","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.jtocrr.2024.100742","article-title":"Brief report of a new anatomical region at risk in thoracic radiotherapy: from discovery to implementation","volume":"5","author":"Banfill","year":"2024","journal-title":"JTO Clin Res Reports"},{"key":"10.1016\/j.canrad.2025.104779_bib0615","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2004.12.025","article-title":"Dose\u2013volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy","volume":"62","author":"Kim","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0620","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0625","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2004.06.014","article-title":"Dosimetric and clinical predictors for radiation-induced esophageal injury","volume":"61","author":"Ahn","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0630","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.radonc.2005.10.001","article-title":"Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer","volume":"77","author":"Chapet","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0635","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0640","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-717X-7-50","article-title":"Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review","volume":"7","author":"Rodr\u00edguez-Ruiz","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0645","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.ijrobp.2008.03.004","article-title":"Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer","volume":"72","author":"Hall","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0650","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.ijrobp.2011.06.1961","article-title":"Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer","volume":"82","author":"Amini","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0655","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0660","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","article-title":"ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer","volume":"152","author":"Le P\u00e9choux","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0665","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0670","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.20.03364","article-title":"Radiation therapy for small-cell lung cancer: ASCO guideline endorsement of an ASTRO guideline","volume":"39","author":"Daly","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0675","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0680","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","article-title":"Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer","volume":"22","author":"Fried","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0685","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/annonc\/mdt140","article-title":"Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer","volume":"24","author":"Sun","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0690","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdw263","article-title":"Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis","volume":"27","author":"De Ruysscher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0695","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0700","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0705","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2019.02.010","article-title":"Consolidative thoracic radiotherapy in stage IV small cell lung cancer: selection of patients amongst European IASLC and ESTRO experts","volume":"135","author":"Putora","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0710","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104779_bib0715","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0720","doi-asserted-by":"crossref","first-page":"110014","DOI":"10.1016\/j.radonc.2023.110014","article-title":"Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: a systematic review and meta-analysis","volume":"190","author":"Feng","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0725","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0730","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0735","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0740","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0745","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2023.41.16_suppl.8512","article-title":"Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)","volume":"41","author":"Gronberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0750","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","article-title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0755","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/0284186X.2015.1092584","article-title":"Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer","volume":"55","author":"Gr\u00f8nberg","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0760","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijrobp.2014.09.042","article-title":"Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer","volume":"91","author":"Xia","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0765","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijrobp.2021.05.003","article-title":"Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: a multicenter, phase II, randomized trial","volume":"111","author":"Qiu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104779_bib0770","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2020.05.004","article-title":"Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer\u00a0\u2013\u00a0Decision criteria in routine practise","volume":"150","author":"Glatzer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0775","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","article-title":"Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive disease small cell lung cancer (ED-SCLC): NRG Oncology RTOG 0937","volume":"12","author":"Gore","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0780","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.32586","article-title":"Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses","volume":"126","author":"Hu","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104779_bib0785","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.radonc.2006.07.029","article-title":"Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial","volume":"80","author":"De Ruysscher","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0790","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group","volume":"341","author":"Aup\u00e9rin","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0795","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0800","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0805","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0810","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdq576","article-title":"Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)","volume":"22","author":"Le P\u00e9choux","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0815","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1470-2045(09)70101-9","volume":"10","author":"Le P\u00e9choux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0820","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2024.11.011","article-title":"Prophylactic cranial irradiation for patients with SCLC-a new perspective in the immunotherapy era","volume":"20","author":"Levy","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0825","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104779_bib0830","doi-asserted-by":"crossref","first-page":"S1267","DOI":"10.1016\/j.annonc.2024.08.2324","article-title":"LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial","volume":"35","author":"Senan","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.canrad.2025.104779_bib0835","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0840","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1200\/JCO.21.00639","article-title":"Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR Study","volume":"39","author":"de Dios","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104779_bib0845","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jtho.2020.12.024","article-title":"Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)","volume":"16","author":"Belderbos","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:17:13Z","timestamp":1768738633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":169,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001957"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104779","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy for primary lung cancer: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104779"}}